Experimental observations on flufenamic, mefenamic, and meclofenamic acids. IV. Toleration by normal human subjects.
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001241:Aspirin / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000032:analysis; D001777:Blood Coagulation / Q000187:drug effects; D001806:Blood Urea Nitrogen; D002712:Chlorides / Q000652:urine; D002986:Clinical Trials as Topic; D003248:Constipation / Q000139:chemically induced; D003967:Diarrhea / Q000139:chemically induced; D004064:Digestive System / Q000187:drug effects; D004361:Drug Tolerance; D005076:Exanthema / Q000139:chemically induced; D005414:Flatulence / Q000139:chemically induced; D005439:Flufenamic Acid / Q000008:administration & dosage / Q000009:adverse effects; D005461:Fluorine / Q000009:adverse effects; D006261:Headache / Q000139:chemically induced; D006356:Heartburn / Q000139:chemically induced; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D008528:Mefenamic Acid / Q000008:administration & dosage / Q000009:adverse effects; D008722:Methods; D009120:Muscle Cramp / Q000139:chemically induced; D009780:Occult Blood; D010919:Placebos; D011188:Potassium / Q000652:urine; D011516:Prothrombin / Q000032:analysis; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D012964:Sodium / Q000627:therapeutic use / Q000652:urine; D014527:Uric Acid / Q000652:urine; D014717:Vertigo / Q000139:chemically induced; D014786:Vision Disorders / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced; D014859:Warfarin / Q000627:therapeutic use; D062367:ortho-Aminobenzoates / Q000009:adverse effects*
D000893:Anti-Inflammatory Agents; D001713:Biphenyl Compounds; D002712:Chlorides; D010919:Placebos; D062367:ortho-Aminobenzoates; D014527:Uric Acid; D005461:Fluorine; D008528:Mefenamic Acid; D014859:Warfarin; D005439:Flufenamic Acid; D011516:Prothrombin; D012964:Sodium; D001241:Aspirin; D011188:Potassium